Given those robust outcomes, we have hypothesised that mfPOP has potential to monitor early stage diabetes-related retinal and nerve dysfunction and, in addition might be useful as a clinical test to assess more generalised diabetes-related tissue injury, that may be superior to other measures such as skin advanced glycation end product (AGE) accumulation and the urine albumin excretion rate. The gene discussed is ALB; the disease is diabetes mellitus.